Search

Search Results

• 

  New approved drugs for psoriatic arthritis

  F.M. Perrotta, E. Lubrano

  57-64

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.873

  3111

  PDF: 2193
• 

  Effects of secukinumab on serum adipocytokines: preliminary data

  A. Fassio, D. Gatti, P. Gisondi, G. Girolomoni, O. Viapiana, A. Giollo, M. Zamboni, M. Rossini, L. Idolazzi

  105-110

  21-09-2017

  https://doi.org/10.4081/reumatismo.2017.953

  2734

  PDF: 1417
• 

  Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

  G. Adami, L. Idolazzi, C. Benini, E. Fracassi, A. Carletto, O. Viapiana, D. Gatti, M. Rossini, A. Fassio

  08-05-2023

  https://doi.org/10.4081/reumatismo.2023.1559

  1580

  PDF: 872
• 

  Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review

  Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

  27-01-2025

  https://doi.org/10.4081/reumatismo.2025.1694

  1476

  PDF: 15
• 

  Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study

  F.M. Perrotta, A. Delle Sedie, S. Scriffignano, P. Volpe, E. Cordisco, N. Milano, M. Gabini, E. Lubrano

  52-59

  10-04-2020

  https://doi.org/10.4081/reumatismo.2020.1266

  1921

  PDF: 1078